Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.75 |
| ▸ | CDK4 | P11802 | 6/20 | 0.75 |
| ▸ | CDK1 | P06493 | 3/20 | 0.57 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102089 | 0.90 | CDK2 (0.76) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL4025355 | 0.86 | CDK2 (0.64) | CDK2CDK4CDK1IKBKBSYK | |
| SCHEMBL4818566 | 0.86 | CDK2 (1.00) | CDK2CDK4CDK1 | |
| SCHEMBL5108640 | 0.85 | CDK2 (0.81) | CDK2CDK4CDK1 | |
| SCHEMBL5095501 | 0.84 | CDK2 (0.80) | CDK2CDK4CDK1 | |
| SCHEMBL5098635 | 0.83 | CDK2 (0.79) | CDK2CDK4CDK1 | |
| SCHEMBL5098833 | 0.82 | CDK2 (0.74) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL4864992 | 0.81 | CDK2 (0.80) | CDK2CDK4CDK1 | |
| SCHEMBL6593918 | 0.81 | CDK2 (0.90) | CDK2CDK4CDK1 | |
| SCHEMBL4864795 | 0.80 | CDK2 (0.75) | CDK2CDK4CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442697-B2 | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-20060074096-A1 | 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity | MOTOROLA MOBILITY LLC | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074096-A1 | 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity | CCNI, CDK3, CDK4 | CDK2 6/4885CDK4 3/4885CDK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.